Potassium Citrate

證據等級: L5

預測適應症: 10 個

Potassium Citrate: From Established Urinary Alkalinisation Use to Nephrolithiasis

One-Sentence Summary

Potassium citrate is a well-known urinary alkaliniser/citrate supplement; the evidence pack’s highest-scoring TxGNN prediction (familial visceral myopathy, 99.95%) has zero supporting evidence and is flagged as likely model noise. The strongest, actionable signal in this bundle is nephrolithiasis, with 35 clinical trials and 19 publications identified — though this largely confirms an existing established use of the drug rather than a genuinely novel indication.

Note: This evidence pack bundles 10 TxGNN-predicted indications for potassium citrate. Nine of them (familial visceral myopathy, mitochondrial OXPHOS disorder, Pendred syndrome, cystinosis, hypermanganesemia with dystonia, SLC26A1-related nephrolithiasis susceptibility, nonsyndromic deafness, exocrine pancreatic insufficiency, leukocyte adhesion deficiency) have Evidence Level L4–L5 with “Hold” or “Research Question” status and no or minimal direct evidence. This report focuses on the one candidate with substantive evidence and an actionable recommendation — nephrolithiasis.

Quick Overview

Item	Content
Original Indication	Not documented in evidence pack (`original_indications` empty, MOA data gap). Potassium citrate is generically known as a urinary alkaliniser/citrate/potassium supplement.
Predicted New Indication	Nephrolithiasis
TxGNN Prediction Score	99.75%
Evidence Level	L1
Australia Market Status	Not marketed
Number of ARTG Entries	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in this evidence pack (flagged as a High-severity data gap). Based on known pharmacology, potassium citrate is a citrate/alkalinising salt: its established effect is to raise urinary pH and increase urinary citrate excretion, which chelates calcium and inhibits calcium oxalate/calcium phosphate crystal formation, and also raises urinary pH to help dissolve uric acid stones.

This is a textbook-level mechanism that maps directly onto nephrolithiasis (particularly calcium and uric acid stone prevention/treatment). Unlike a typical TxGNN repurposing hypothesis, the rationale text in this evidence pack notes that this indication is essentially an existing standard clinical use of the drug rather than a novel prediction — the model has effectively re-identified a well-established therapeutic role.

Two related but weaker hypotheses appear in the same bundle: cystinosis (L4, Research Question) — plausible because nephropathic cystinosis often causes proximal tubular Fanconi syndrome with bicarbonate/citrate wasting, but no trial has tested potassium citrate in this population directly — and exocrine pancreatic insufficiency (L4, Research Question) — supported only by a single case report of citrate treating secondary oxalate nephropathy. Both would need dedicated hypothesis-generation work before further evaluation.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT01217372	Phase 2	Completed	203	LIMONE study — open-label, blinded-endpoint RCT testing citrate/lemon-juice supplementation to prevent recurrence of calcium oxalate nephrolithiasis
NCT06966635	Phase 4	Recruiting	312	Sustained-release potassium citrate vs sodium bicarbonate vs control for gout, evaluating alkalinisation effects on uric acid lowering and urinary calculi prevention
NCT05365477	Phase 4	Completed	56	Randomised trial of empiric vs selective (metabolic-workup-guided) diet-plus-pharmacologic prevention strategies in high-risk stone formers
NCT00004284	Phase 3	Completed	300	Double-blind RCT comparing slow-release potassium phosphate vs potassium citrate for absorptive hypercalciuria and stone recurrence prevention
NCT01754779	Phase 2	Completed	13	Evaluated whether citric acid or potassium citrate reduces calcium phosphate saturation in urine of calcium phosphate stone formers
NCT01980004	Phase 2	Withdrawn	0	Designed to compare potassium citrate + dietary education vs dietary education alone for calcium phosphate stone recurrence; trial withdrawn, no data
NCT06819553	Phase 2/3	Active, not recruiting	48	RCT evaluating oral potassium citrate for reducing ureteral stent encrustation after ureteroscopy for uric acid stones
NCT01329042	Phase 4	Completed	80	Evaluated potassium sodium citrate for preventing stone recurrence/residual fragment growth after shockwave lithotripsy and PCNL in calcium oxalate urolithiasis
NCT03258190	Phase 2	Completed	137	Lime powder regimen (citrate/citric acid + potassium) tested against standard therapy for urinary metabolic abnormalities and urolithiasis recurrence
NCT00120731	N/A	Withdrawn	0	Planned study of urinary chemistry and acid-base effects of potassium citrate in children with idiopathic hypercalciuria and urolithiasis; withdrawn

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27915395	2017	Systematic review/meta-analysis	Urolithiasis	Meta-analysis of RCTs on potassium citrate supplementation for preventing stone recurrence before/after shockwave lithotripsy
39206631	2024	Phase II study	Urologia	Oral potassium citrate + magnesium + probiotics reduced crystalluria in stone formers
40978115	2025	Review	Clinical Kidney Journal	Comprehensive update on citrate biology, renal handling, and clinical use in calcium stone disease
33417997	2021	Preclinical (animal model)	Kidney International	Chlorthalidone + potassium citrate reduced calcium oxalate stones and improved bone quality in genetic hypercalciuric rats
30531474	2019	Review	Curr Opin Nephrol Hypertens	Reviews role of citrate therapy specifically in calcium phosphate stone disease
3306318	1987	Review	Miner Electrolyte Metab	Classic paper establishing potassium citrate’s role in renal tubular acidosis with calcium stones, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis
26150027	2015	Review	Arch Ital Urol Androl	CLU Working Group review of dietary/citrate interventions for urinary stone risk factors
40583613	2025	Guideline/Review	Arch Ital Urol Androl	Expert consensus (ESD 2025) on management of urinary stones, including citrate-based prevention
38583757	2024	Cohort	Am J Kidney Dis	Evaluated independent associations between 24-hour urinary chemistries (including citrate) and kidney stone risk
16443041	2006	Review	Lancet	General overview of kidney stone pathophysiology and medical management, including citrate therapy

Australia Market Information

Potassium citrate currently has no ARTG entries in Australia (market status: not marketed, 0 licenses recorded). No approved local product information is available at this time.

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. No key warnings, contraindications, or drug interaction data were returned in this evidence pack (DDI query: not found).

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Nephrolithiasis is supported by L1-grade evidence (multiple completed Phase 2–4 RCTs, including a Phase 3 comparator trial and a published meta-analysis), and the mechanism is well-established rather than speculative — potassium citrate is already a recognised therapy for calcium and uric acid stone prevention internationally. However, it is currently unregistered in Australia (0 ARTG entries) and safety/MOA documentation is a blocking data gap.

To proceed, the following is needed:

TGA Product Information / label data (currently a Blocking data gap — no ARTG entry to source it from)
Formal mechanism-of-action documentation (High-severity data gap)
A regulatory pathway assessment for ARTG registration, since the drug is not currently marketed in Australia
If pursuing the secondary hypotheses (cystinosis, exocrine pancreatic insufficiency), dedicated clinical evidence generation, as current support is limited to case reports/mechanistic inference only
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.